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Type 2 diabetes is becoming the leading cause of end-stage
renal disease (ESRD) worldwide. Prevalence of ESRD and the
antihypertensive response to renin–angiotensin system
intervention are suggested to vary among different
ethnicities. The Reduction in Endpoints in Non-insulin
dependent diabetes mellitus with the Angiotensin II
Antagonist Losartan (RENAAL) study, which included
different ethnic groups, demonstrated a renoprotective effect
of losartan. A post hoc analysis from RENAAL was performed
where we examined in each ethnic group the ESRD risk,
identified independent predictors for ESRD, effect of degree
of baseline albuminuria, effect of 6-month antiproteinuric
response to therapy on ESRD, and renoprotective effect of
losartan assessed by albuminuria reduction and ESRD.
Baseline albuminuria was the strongest predictor for ESRD in
every ethnic group. Albuminuria reduction was associated
with reduced risk of ESRD while losartan reduced albuminuria
in every ethnic group. When accounting for independent
predictors of ESRD, losartan exhibited renoprotection in all
ethnic groups. In this type 2 diabetic population with
nephropathy, baseline albuminuria is the predominant risk
parameter for ESRD; early antiproteinuric effect of losartan
predicts long-term renoprotection; and losartan appears to
be renoprotective in all ethnic groups. Since the RENAAL
study was not powered to determine ethnic responses, these
results underline the need for prospective trials where the
aim is renal protection among different ethnic groups.
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Worldwide, diabetes mellitus is one of the most common
diseases1 and has become a major cause of end-stage renal
disease (ESRD).2,3 Ethnic differences in ESRD have been
widely reported. Earlier and more recent population-based
studies consistently have shown that in diabetic and non-
diabetic patients, Black, and in some reports, Asian patients,
experience higher rates of ESRD, whereas White patients
experience lower rates.4–8 Higher incidences of ESRD have
been reported in Hispanic patients with or without diabetes,
relative to White patients.2,7–9
Given the fact that nephropathy occurs in approximately
10–40% of diabetic patients,10 early identification of patients
with type 2 diabetes who are at increased risk for renal disease
and early initiation of treatment to slow progression to ESRD
is of great importance for all ethnic groups. Proteinuria,
azotemia, anemia, hyperglycemia, hypertension, and hyper-
lipidemia have been shown to be risk factors for renal and
cardiovascular outcomes in type 2 diabetes.11–15 However,
whether these risk factors for outcome play the same
predictive role among different ethnicities is not known.
Proteinuria is one of the most widely recognized risk factors
for renal disease progression.16–18 Proteinuria has been
studied in different ethnic groups; however, the findings
have been variable with respect to the prevalence and severity
of proteinuria among those groups.19–25
Several large clinical trials have shown that intervention
using antihypertensives that block the renin—angiotensin
system (RAS) are beneficial in reducing the incidence of
cardiovascular and renal outcomes in diabetic patients.26–29
Whether such a treatment strategy is equally beneficial to
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2006 International Society of Nephrology
Received 18 January 2005; revised 19 November 2005; accepted 14
December 2005; published online 29 March 2006
Correspondence: D de Zeeuw, Department of Clinical Pharmacology,
University Medical Center Groningen, Ant Deusinglaan 1, Groningen 9713
AV, The Netherlands. E-mail: d.de.zeeuw@med.umcg.nl
Kidney International (2006) 69, 1675–1682 1675
diabetic patients across different ethnicities is not known. In
fact, it has been suggested that the antihypertensive response to
RAS blockade is less effective than other therapeutic classes in
Black patients relative to non-black patients.30,31 However,
limited data are available on the effect of RAS blockade on
cardiovascular and renal outcomes comparing different
ethnic groups simultaneously and prospectively.
The Reduction in Endpoints in Non-insulin dependent
diabetes mellitus with the Angiotensin II Antagonist Losartan
(RENAAL) study was the first to demonstrate that RAS
blockade with losartan is effective in reducing the incidence
and delaying the onset of ESRD in patients with type 2
diabetes and nephropathy.29 Additionally, baseline protein-
uria has been shown to be the leading risk predictor for renal
outcomes including ESRD in this population.12 Furthermore,
angiotensin II antagonist (AIIA)-induced reduction in
proteinuria appears to be a good predictor for long-term
renal and cardiovascular protection.11,12 The RENAAL study,
to our knowledge, is the only study that has recruited type 2
diabetic patients with renal disease worldwide, including
relatively large numbers of White, Black, Hispanic, and Asian
patients. ESRD was observed in each ethnic group, which has
allowed us to explore risk of renal outcomes and the
renoprotective effect of losartan therapy across those groups.
We also investigated if similar renal risk factors are present in
each ethnic group. Moreover, in each ethnic group, we
examined whether the reduction in albuminuria affords the
same renal protection, and whether RAS intervention with
losartan leads to the same risk reduction in ESRD. In the
present report, we focus on the irreversible renal outcome of
ESRD, as this outcome was ascertained in all patients
randomized to the study, and represents the final stage of
renal disease progression, and the ultimate therapeutic target
for renal protection.
RESULTS
Baseline risk factors as predictors of ESRD by ethnic group
Table 1 summarizes baseline demographic parameters for the
RENAAL population stratified by ethnic group. We observed
expected differences in weight among the ethnic groups, with
the Asian patients having the lowest weight (64 kg) and the
Black and White patients having the highest weights (92 and
88 kg, respectively) in the study.
Hemoglobin was lowest in the Black patients and highest
in White patients (12.0 and 12.8 mg/dl, respectively). Serum
creatinine, systolic blood pressure (BP), and diastolic BP were
comparable among all ethnic groups. Notable differences
were observed among the groups in baseline albuminuria,
which was considerably higher in Hispanic and Asian
patients (2.40 and 2.01 g/g, respectively) and lowest in Black
patients (1.22 g/g). Figure 1 clearly illustrates that the
distribution of baseline albuminuria levels varied among
ethnic groups.
The risk for ESRD among ethnic groups is depicted in
Figure 2. The Hispanic and Asian populations show a
somewhat higher risk for ESRD than the Black and White
populations. A multivariate analysis was performed to
determine the relative impact of selected baseline risk factors
on ESRD in the different ethnic groups. Table 2 shows that of
the selected baseline risk factors included in the multivariate
model, baseline albuminuria was the strongest independent
predictor of ESRD in all ethnic groups: Asian (hazard ratio
(HR)¼ 1.33), Black (HR¼ 1.81), Hispanic (HR¼ 1.46), and
White (HR¼ 1.62).
The distribution of baseline albuminuria was variable
among ethnic groups. Despite these differences, we observed
that a similar degree of albuminuria predicted a similar
degree of risk for ESRD across ethnic groups. As shown in
Figure 3, higher levels of baseline albuminuria were associ-
ated with progressively increased risk of ESRD (controlled
for baseline risk factors) for all ethnic groups.
Six-month change in albuminuria as a predictor for ESRD by
ethnic group
Data from the RENAAL study suggest that albuminuria
reduction observed in the first 6 months of treatment is
predictive of the efficacy of treatment on renal outcomes.12
The relationship between different degrees of month-6
albuminuria reduction and the risk for ESRD is depicted in
Figure 4 for each ethnic group. Similar to the overall
population,12 albuminuria reduction was associated with
reduced risk of ESRD (controlled for baseline and changes in
month-6 risk factors) in all ethnic groups.
Renoprotective effect of losartan by ethnic group
Losartan-reduced albuminuria in the overall population by
34%.29 Figure 5 illustrates mean change in albuminuria
during the course of the study in each ethnic group. Over
time, mean reductions in albuminuria were observed in the
placebo groups of each ethnic group, especially after the first
12 months of the study. The albuminuria reductions with
placebo most likely were influenced by premature disconti-
nuation of study drug, ESRD or death. Progressive reductions
in albuminuria with losartan were observed as early as
month-3 in all ethnic groups (Figure 5).
The renoprotective effect of losartan in the overall
RENAAL population was characterized by a 28% risk
reduction in ESRD when comparing losartan to placebo,
with both treatment groups on a background of conventional
antihypertensive treatment.29 Figure 6 illustrates the losartan
treatment effect for ESRD by ethnic group. The renoprotec-
tive effect of losartan based on the pre-specified analysis
(Figure 6, solid lines), was most favorable in the White and
Asian groups followed by the Black group; while a neutral
treatment effect for ESRD was observed in the Hispanic
ethnic group. However, given the importance of baseline
albuminuria and other variables as independent predictors of
risk, the treatment effects for ESRD for each ethnicity were
controlled for their respective baseline risk predictors
identified in the multivariate analysis (Table 2). The
renoprotective response of losartan when accounting for
these risk factors (Figure 6, dashed lines) was improved in all
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ethnic groups, especially in Hispanic patients, where the HR
fell from 1.02 (95% confidence interval (CI): 0.66, 1.59) to
0.81 (95% CI: 0.52, 1.27).
In each ethnic group, the potential impact of BP changes
on the treatment effect for ESRD was examined. Table 3
presents treatment effect of losartan based on the pre-
specified analysis (depicted by the solid lines in Figure 6) and
after adjustment for systolic and diastolic BP as a time-
varying covariate (post-randomization). Treated BP does not
appear to have a notable impact on the treatment effect for
ESRD, as the HRs for the ethnic groups after adjusting for
time-varying BP remain stable or slightly increased (Table 3).
Table 1 | Patient demographic and other baseline characteristics by ethnic group
Variable Statistics Asian Black Hispanic White
Gender N 252 230 277 735
Female n (%) 81 (32.1) 94 (40.9) 128 (46.2) 243 (33.1)
Male n (%) 171 (67.9) 136 (59.1) 149 (53.8) 492 (66.9)
Smoking N 249 230 277 734
Yes n (%) 52 (20.9) 46 (20.0) 43 (15.5) 130 (17.7)
Age (years) N 252 230 277 735
Mean (s.d.) 59.6 (7.3) 59.1 (7.8) 59.0 (7.5) 61.2 (7.2)
Range 36.0–72.0 31.0–73.0 40.0–74.0 34.0–73.0
BMI (kg/m2) N 244 224 269 722
Mean (s.d.) 25.0 (4.5) 32.0 (6.2) 28.3 (6.6) 31.0 (5.7)
Range 15.6–50.5 19.6–56.3 18.0–59.6 16.1–53.9
Weight (kg) N 252 230 277 735
Mean (s.d.) 64.3 (13.1) 92.2 (19.1) 73.6 (19.6) 88.2 (18.7)
Range 32.0–132.2 48.1–159.7 40.0–161.0 48.1–158.8
DBP (mmHg) N 252 230 277 735
Mean (s.d.) 81.5 (10.8) 82.7 (11.1) 82.4 (9.4) 82.5 (10.5)
Range 37.0–111.0 55.0–120.0 53.0–108.0 43.0–117.0
SBP (mmHg) N 252 230 277 735
Mean (s.d.) 151.8 (19.3) 149.9 (18.6) 150.3 (19.7) 154.5 (19.3)
Range 105.0–199.0 107.0–199.0 97.0–200.0 100.0–226.0
HBA1c (%) N 249 226 277 726
Mean (s.d.) 8.1 (1.5) 8.9 (1.7) 8.8 (1.9) 8.3 (1.5)
Range 4.8–13.2 5.0–13.9 5.1–17.5 4.8–13.4
Hemoglobin (gm/dl) N 239 226 273 711
Mean (s.d.) 12.2 (2.0) 12.0 (1.7) 12.3 (1.9) 12.8 (1.7)
Range 7.9–17.1 7.8–15.9 6.8–17.4 8.4–18.0
Serum creatinine (mg/dl) N 252 230 277 735
Mean (s.d.) 1.9 (0.4) 1.8 (0.5) 1.9 (0.5) 1.9 (0.5)
Range 1.0–3.1 1.1–3.3 0.9–3.4 1.0–3.6
Cholesterol (mg/dl) N 252 228 276 723
Mean (s.d.) 228.0 (51.2) 222.7 (53.8) 237.6 (56.1) 225.4 (56.5)
Range 126.0–426.0 120.0–402.0 114.0–495.0 97.0–480.0
Albuminuria (g/g) N 252 230 277 735
Mean (s.d.) 2.01 (1.72) 1.22 (1.19) 2.40 (2.13) 1.69 (1.53)
(GM) (1.35) (0.78) (1.62) (1.10)
Range 0.03–10.15 0.03–7.70 0.09–12.21 0.03–9.95
Proteinuriaa (g/day) N 42 144 193 330
Mean (s.d.) 3.12 (2.94) 2.63 (2.50) 4.30 (4.01) 3.39 (3.54)
(GM) (2.02) (1.75) (2.85) (2.15)
Range 0.11–13.49 0.19–11.97 0.37–23.25 0.03–23.82
BMI: body mass index; DBP: diastolic blood pressure; GM: Geometric mean; SBP: systolic blood pressure.
The analysis was based on observed data without imputation on missing values.
aSubgroup of patients in whom 24 h urine was collected (see Materials and Methods section).
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DISCUSSION
For all ethnic groups (i.e. Asian, Black, Hispanic, and White),
the most important, independent, baseline factor that
determines renal risk for ESRD is albuminuria (higher
albuminuria associated with greater renal risk), followed by
either baseline serum creatinine or hemoglobin. In this study,
the risk for ESRD appears to be higher in the Hispanic and
Asian ethnic groups. We found that treatment induced
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Figure 1 | Distribution of baseline albuminuria stratified by
ethnic group. Each box represents albuminuria levels by quantiles.
The lowest and highest boundaries below and above each box
represent the 10th and 90th% quantiles, respectively. The bottom,
middle, and top of each box represent the 25th, 50th, and 75th%
quantiles, respectively.
12 24 36 48
Months
0
10
20
30
40
50
En
d-
st
ag
e 
re
na
l d
ise
as
e 
(%
)
No. at risk
Asian White
Black
Hispanic
Asian 252 237 212 94 12
Black 230 221 198 113 16
Hispanic 277 253 209 122 16
White 735 700 602 384 66
Figure 2 | Event rate of ESRD stratified by ethnic group. The
cumulative proportion (%) of patients in each ethnic group that
reached ESRD was estimated using the Kaplan–Meier procedure.
Table 2 | Multivariate analysis for the effect of baseline risk
markers on ESRD (ordered by v2 statistics)
Ethnic
group
Independent
base risk factorsa HR (95% CI) v2 P-value
Asian Albuminuria 1.33 (1.19, 1.48) 27.0 0.000
Hemoglobin 0.70 (0.60, 0.82) 20.6 0.000
Age 0.60 (0.41, 0.87) 7.1 0.008
Black Albuminuria 1.81 (1.53, 2.14) 48.4 0.000
Serum creatinine 8.03 (4.25, 15.17) 41.1 0.000
Hispanic Albuminuria 1.46 (1.35, 1.58) 94.0 0.000
Serum creatinine 3.15 (2.06, 4.81) 28.1 0.000
White Albuminuria 1.62 (1.49, 1.75) 134.0 0.000
Serum creatinine 5.02 (3.70, 6.82) 106.8 0.000
Male vs. Female 0.52 (0.37, 0.73) 14.1 0.000
CI: confidence interval; ESRD: end-stage renal disease; HR: hazard ratio.
All patients were included with missing covariates imputed.
aSelected from baseline covariates listed in the Statistical analysis section.
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Figure 3 | Risk for ESRD versus baseline albuminuria stratified by
ethnic group. The HR with 95% CI is referenced at albuminuria
o0.5 g/g in White patients. HR is controlled for all baseline risk
markers summarized in the Statistical analysis section.
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Figure 4 | Risk for ESRD versus albuminuria reduction stratified
by ethnic group. The HR with 95% CI is calculated relative to 0%
change in albuminuria. The HR is controlled for all risk markers at
baseline and month-6 changes, summarized in the Statistical analysis
section.
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Figure 5 | Mean percent change from baseline in albuminuria
over time stratified by ethnic group.
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change in albuminuria at month-6 predicts the longer-term
renoprotective effect in a similar manner for Black, Asian,
Hispanic, and White patients. Controlling for differences in
baseline risk profile for each ethnic group, our results indicate
that losartan affords renoprotection with regard to ESRD and
reduction in albuminuria, irrespective of ethnicity.
Although many large clinical studies examining the effect
of treatment on renal outcome were multinational, all of
them were conducted in a limited number of geographical
regions.19,28,32–35 Unlike these studies, RENAAL was not only
carried out in multiple regions of the world, which included
North and South America, Europe, and Asia (southeast
region and Japan); but also resulted in similar numbers of
patients in the Asian, Black, and Hispanic populations. For
this reason, RENAAL provides the opportunity to evaluate
renal risk factors and treatment effect on renal outcomes
across these ethnic groups.
There are many published reports showing that among
ethnic groups, the greatest occurrence of ESRD is observed in
Black patients.4–8 Interestingly, our findings show that Asian
and Hispanic patients had similarly higher event rates for
ESRD compared to Black and White patients. However, the
variation in event rates accords well with the observed
baseline albuminuria distribution among ethnic groups. We
observed higher baseline albuminuria levels in the Asian and
Hispanic patients, the same groups that experienced higher
ESRD rates, while albuminuria levels and ESRD incidence
rates were lower in the Black followed by White patients. This
relationship between albuminuria and ESRD is consistent
with our findings that higher baseline albuminuria categories
are associated with higher risk for ESRD across all ethnic
groups. These results support the findings of Keane et al.36
and Zhang et al.37 demonstrating that there is a clear
association between baseline albuminuria and risk for ESRD
in the overall RENAAL population.
Several risk factors, such as hypertension,38,39 hyperglyce-
mia,14 and hyperlipidemia15 appear to be associated with
progression of renal disease in diabetes. However, proteinuria
and hypertension are the most widely recognized risk factors
for renal disease in diabetic and non-diabetic pa-
tients.17,33,40,41 The predictive nature of proteinuria or other
risk factors for renal disease in ethnic groups has not been
previously examined. The current analysis demonstrates that
baseline albuminuria is the strongest, independent risk
predictor for ESRD in all the ethnic groups studied,
regardless of the variations in baseline albuminuria level
among the different populations. These findings are con-
sistent with conclusions reported for the overall RENAAL
population.12
Ethnic differences in response to therapy have been widely
reported. However, we are not aware of data illustrating the
impact of treatment on ESRD, in different ethnic popu-
lations. There is evidence indicating that the antihypertensive
effects of RAS intervention with angiotensin-converting
enzyme inhibitors or AIIAs as monotherapy are less
pronounced compared to other therapeutic classes in
Black42–44 and Asian44 patients. Diminished antihypertensive
efficacy with RAS intervention in Hispanic and White
patients has not been reported.44
It has been consistently reported that reduction in
proteinuria with angiotensin-converting enzyme inhibition
is a reliable marker for renal protection in non-diabetic
patients.16,33 Findings from the RENAAL study have
demonstrated that treatment-induced changes in albumin-
uria are associated with renal protection in type 2 diabetic
patients.12 We therefore sought to determine whether
treatment-induced changes in albuminuria existed in each
0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8
Hazard ratio
Asian
Black
Hispanic
White
Combined
Controlled for baseline covariates
Prespecified
Figure 6 | ESRD treatment effect of losartan compared to placebo
stratified by ethnic group. The dots and horizontal lines indicate HR
point estimates and 95% CI’s, respectively. The solid and dashed
horizontal lines represent the analyses without (pre-specified) and
with controlling for baseline covariates as summarized in Statistical
analysis section, respectively. The vertical line indicates a reference
HR of 1.0, or no difference between treatment groups.
Table 3 | Treatment effect of losartan on ESRD by ethnic group
Race
Losartan Placebo
Pre-specified Adjusted
N Event (rate) N Event (rate) HR (95% CI) HR (95% CI)
Asian 117 22 (66.6) 135 37 (102) 0.63 (0.37, 1.07) 0.64 (0.37, 1.09)
Black 125 22 (59.4) 105 22 (72.0) 0.83 (0.46, 1.52) 0.93 (0.51, 1.69)
Hispanic 140 42 (111) 137 39 (108) 1.02 (0.66, 1.59) 1.14 (0.73, 1.77)
White 358 58 (54.5) 377 90 (84.1) 0.60 (0.43, 0.83) 0.62 (0.45, 0.87)
BP: blood pressure; CI: confidence interval; ESRD: end-stage renal disease; HR, hazard ratio.
All patients (except patients with other race) were included with missing covariates imputed.
Event: no. of patients with ESRD; rate: event rate per 1000 years of follow-up; pre-specified: a Cox model with treatment group and region as covariates and baseline
proteinuria level (o or X2 g/g) as strata; adjusted: a multivariate Cox model with treatment group, time-varying systolic and diastolic BP as covariates.
Pre-specified analysis and adjusted for time-varying BP.
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ethnic group and whether a similar reduction in albuminuria
would lead to similar renal protection among the different
ethnic groups. Indeed, the current analysis shows that a
progressive decline in albuminuria from baseline is observed
in all ethnic groups. Interestingly, the magnitude of reduction
varies among ethnic groups; however, the quantitative
relationship between degree of albuminuria reduction and
degree of renal protection appears to be similar across ethnic
groups.
Regardless of the reported ethnic differences in response to
RAS intervention, the present analysis shows that treatment
with losartan affords renal protection as assessed by a
reduction in ESRD in all ethnic groups. In the pre-specified
analysis, a favorable treatment effect on ESRD was detected in
Asian, Black, and White patients, whereas a neutral treatment
effect was observed in Hispanic patients. We found that the
observed differences in treatment effect among ethnic groups
may be explained by treatment group imbalances in baseline
albuminuria, the strongest risk predictor for all ethnic
groups. Accounting for baseline imbalances (among treat-
ment groups) in albuminuria and other independent risk
factors, improved treatment effects on ESRD with losartan
was observed across all ethnic groups, most notably in
Hispanic patients. Not surprisingly, in all ethnic groups,
baseline albuminuria had the greatest impact of all the risk
factors on the improved treatment effects (data not shown).
All ethnic groups experienced decreases in diastolic BP
and systolic BP with losartan (data not shown). Of note, the
Asian group experienced significantly greater systolic BP
reductions from baseline in the losartan versus placebo
groups. For each ethnic group, we explored the effect of
treated BP as a time-varying covariate on treatment effect for
ESRD. The results of this analysis suggest that treated BP did
not have a notable impact on treatment effect on ESRD in
each ethnic group.
Certainly, factors other than biological risk parameters
may have played a role in the treatment effect on ESRD. The
Asian patients in the RENAAL study had the lowest rate of
discontinuation from study therapy,45 while notably higher
discontinuation rates were observed across the other ethnic
groups. It is plausible that study therapy compliance may
have been an important factor in the degree of benefit
derived from losartan treatment. We assessed the body
weight-adjusted dose of losartan across ethnic groups and did
not find a relationship between losartan dose (weight
adjusted) and the observed differences in treatment effect
on ESRD among these groups. And other factors that cannot
be quantitated, such as lifestyle and medical environment
differences may have played a role in the treatment effect of
losartan. In the pre-defined subgroup analysis, no statistical
interaction between ethnicity and treatment was detected for
ESRD (data not shown).
The RENAAL study was not designed to make compar-
isons across ethnic groups. Therefore, the observed variations
in treatment effect on ESRD and albuminuria reduction
among the four ethnic groups are not unexpected. Neverth-
eless, the results of the present report should be interpreted
with caution as evaluation of losartan’s renoprotective effect
by ethnic group was not the primary aim of the study.
In summary, our findings indicate, for all ethnic groups
studied, the most important, independent baseline risk
predictor for ESRD is albuminuria. The degree of treat-
ment-induced albuminuria reduction is similarly associated
with the degree of long-term renoprotection for all ethnic
groups. Furthermore, in patients with type 2 diabetes and
nephropathy we have shown that losartan confers renopro-
tection, in terms of long-term reduction of albuminuria and
reduced risk for ESRD across ethnic groups. Since the
RENAAL study was not powered to determine ethnic
responses, these results underline the need for prospective
trials where the primary aim is renal protection among
different ethnic groups.
MATERIALS AND METHODS
Patients and study design
Results from the RENAAL study, a multinational, double-blind,
randomized study comparing losartan versus placebo, each in
addition to conventional antihypertensive therapy, excluding
angiotensin-converting enzyme inhibitors and other AIIAs, were
examined. RENAAL was performed in 250 centers across 28
countries. One thousand five hundred and thirteen diabetic patients
with nephropathy were randomized, comprised of 252 Asian, 230
Black, 277 Hispanic, and 735 White patients. Ethnic group
designation was based on patient self-designation during the
enrollment phase. The study design, inclusion/exclusion criteria,
and the treatment protocols have been reported previously.46
Nephropathy was defined as urinary albumin:creatinine ratio
40.3 g/g in a first morning void or a 24-h urine protein 40.5 g
and serum creatinine 41.5 mg/dl in males (41.3 mg/dl in females,
or maleso60 kg) to 3.0 mg/dl. Patients were followed for a mean of
3.4 years. All patients signed informed consent prior to enrollment,
and the study was approved by the local Institutional Review Board
of each participating center.
Before randomization and every 3 months post-randomization,
seated trough BP was measured, blood samples were obtained to
measure chemistry and hematology parameters, and a first morning
urine sample was obtained to measure the albumin:creatinine ratio.
In a subset of patients, 24-h urine samples also were collected in
order to measure total protein. All blood and urine tests were
performed by a central laboratory.
The primary efficacy parameter was a composite end point of
time to the first event of doubling of serum creatinine, ESRD, or
death. ESRD was defined as the need for chronic dialysis or renal
transplantation. Analyses of the components of the primary
composite end point also were pre-specified. Albuminuria (protein-
uria) reduction over time between two treatment groups was one of
the secondary end points.
Statistical analysis
This report is based on 1494 randomized patients. Nineteen of the
1513 patients randomized belonged to ‘other’ ethnic groups and
were excluded from the present analyses.
In the current analysis, ESRD was the end point of interest.
Patients who either died or completed the study without reaching
ESRD were censored at the death date or the study cutoff date of
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February 10, 2001, respectively. There were no lost to follow-up
patients, therefore ESRD outcomes were obtained for all rando-
mized patients.
Albuminuria was assessed using the albumin:creatinine ratio
from a first morning urine sample, and designated ‘albuminuria’
throughout this report. Albuminuria change at month-6 for each
patient was calculated as 100 percent (1ratio of albuminuria at
month-6 over baseline). Changes in albuminuria during the study
were summarized as the mean percent change from baseline in
albuminuria (on the natural log scale) by treatment groups. The
6-month time interval was selected because at this time, patients had
a scheduled clinic visit, the therapy effect was considered fully
present, and few renal events occurred before month-6.12
The cumulative proportion (%) of the ESRD end point was
estimated using the Kaplan–Meier procedure. Analysis of baseline
risk factors was performed to identify independent risk factors for
ESRD. Baseline risk factors were selected among the following
covariates: age (year/10), gender, weight, smoking, diastolic BP, and
systolic BP, total cholesterol, serum creatinine, hemoglobin, HbA1C,
and albuminuria. For each ethnic group, a two-step selection
procedure was used to determine independent risk predictors for
ESRD: (1) a univariate analysis was performed using a Cox-
regression model for selected covariates in order to identify
covariates with a significance level o0.01; (2) significant covariates
identified from the univariate analysis were included in a multi-
variate Cox-regression model, where a backward selection method
was used with a significance levelo0.01 to identify a covariate as an
independent predictor of ESRD. The strength of a risk factor as an
independent predictor included in the final analysis was determined
by its magnitude of significance using w2 statistics.
The losartan treatment effect was determined with and without
controlling for the baseline covariates as described above. Based
upon the pre-specified analysis for the primary hypothesis,29 a Cox-
regression model was performed with indicators of treatment group
and region as covariates, and baseline albuminuria level (o/X2.0 g/
g) as strata. For the controlled analysis for each ethnicity, region was
replaced with the significant baseline covariates (without pre-
specified albuminuria (o/X2.0 g/g) strata) identified in the
respective baseline multivariate Cox models. The HR (losartan
versus placebo) with 95% CI was calculated. A similar analysis was
pre-specified for the whole population where the primary outcome
was controlled for significant baseline covariates, identified in a
multivariate analysis.
The association between albuminuria and the ESRD end point
was explored for combined treatment group, with baseline
albuminuria stratified into four, post hoc subgroups: o0.5 g/g,
X0.5o1.5 g/g, X1.5o3.5 g/g, and X3.5 g/g with the aim of
providing a smooth risk profile, when controlling for other baseline
risk factors. To show a risk profile over baseline albuminuria among
ethnic groups, a multivariate Cox model was used for all the patients
with indicators of baseline albuminuria category by ethnic group as
covariates, referencing the lowest category (o0.5 g/g) in the White
group. The HR and corresponding 95% CI of each baseline
albuminuria category were controlled for other baseline covariates
described above (with the exception of albuminuria), using a
backward selection method on the variables with alpha¼ 0.01.
To estimate the effect of albuminuria change on ESRD, an
analysis similar to baseline albuminuria was performed when
patients were stratified by three post hoc response groups in albumin-
uria reduction at month-6: o0%, X0o30% and X30%. Selection
of albuminuria categories was based on such considerations
as simple and clinical meaningful cut limits, adequate sample size
per category, and number of patients having events per category.
A cut point of 30% was selected to be consistent with the
approximate overall reduction of albuminuria of 30% that was
observed in this study. The lowest albuminuria reduction category
(o0%) in the White group was used as a common reference to
compute the HR and 95% CI for each of the other ethnic groups. In
addition to baseline covariates, month-6 change variables (weight,
diastolic BP, systolic BP, serum creatinine, HbA1C) were also
included in the controlled multivariate analysis. Month-6 change
for each variable was defined by the difference between month-6 and
baseline values.
Some patients had missing values for relevant baseline and
month-6 parameters. It is important to note, however, that no
patients had missing baseline albuminuria or serum creatinine
values. In order to use the intention-to-treat approach which
includes all randomized patients into the multivariate Cox models,
missing values either at baseline or month-6 were populated initially
by imputation, using linear regression models. Each variable with
missing values at baseline or month-6 was run in the model as a
dependant variable with a set of baseline variables with complete
measurements (independent variables), including albuminuria,
serum creatinine, BP, age, gender, race, and region. The missing
values were predicted from the regression model. Among 1513
randomized patients, there were few missing values (up to 3%,
except 13% for HbA1c at month-6).
Although comparisons for the treatment effect on renal
outcomes across ethnic groups were pre-specified subgroup
analyses, the study was neither powered nor randomized to make
definitive conclusions of the findings presented in this report. Most
analyses presented in this report are post hoc.
All statistical analyses were performed using SAS version 8.
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